Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Apr. 7, 2026 A gene called KLF5 may be a key force behind the spread of pancreatic cancer—but not in the way scientists expected. Rather than mutating DNA, it rewires how genes are turned on and off, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results